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< 0.05 level. CONCLUSIONS: The likelihood of reﬁlling an
SSRI varies by the speciﬁc SSRI and may vary by age, gender,
and copayment amount. Patients are more likely to reﬁll the ﬁrst
prescriptions for sertraline or citalopram than for paroxetine.
PMH67
DEPRESSION DIAGNOSIS IN PRIMARY CARE VISITS NOT FOR
MENTAL HEALTH REASONS 
Singer ME, Propper VH
Case Western Reserve University, Cleveland, OH, USA
OBJECTIVE: To examine factors associated with diagnosis of
depression at a primary care visit for reasons unrelated to depres-
sion. METHODS: We used the 1998–2000 National Ambula-
tory Medical Care Survey for ofﬁce-based physician visits. We
included visits to their primary care physician for patients with
no indication of prior episodes of depression. We excluded
patients under 15 years old and visits where the major reason
for the visit was for mental health or social problems. We created
a multivariate logistic regression model to examine which factors
were associated with a depression diagnosis. Study variables
included: age, race, sex, geographic region, urban setting,
payment source, time spent with physician, new patient, HMO
status, capitated visit, and major reason for the visit. RESULTS:
There were 18,612 patients meeting study criteria, of whom
11,365 (61%) were female, 2,037 (11%) black, 1,940 (10%)
were under age 25 and 5,629 (30%) were at least 65 years old.
A total of 234(1.5%) patients received a depression diagnosis.
Multivariate analysis showed that younger (age 15–24; OR =
0.486, p = 0.0177) and older patients (age 65+; OR = 0.517, p
< 0.0001) were less likely to receive a depression diagnosis.
Factors associated with increased likelihood of depression diag-
nosis: female (OR = 1.81, p < 0.0001), self-pay (OR = 1.64, p =
0.329), and major reason for visit a chronic problem, both
routine (OR = 2.24, p < 0.0001) and ﬂareup (OR = 1.58, p =
0.0349). There were non-signiﬁcant trends towards reduced rate
of diagnosis in blacks (OR = 0.645, p = 0.0811) and visits related
to surgery/injury(OR = 0.343, p = .0620), and towards higher
rates in the West(OR = 1.38, p = 0.0847). There was no associ-
ation between diagnosis of depression and urban setting, new
patient, capitated visit, HMO enrollment. Association of time
spent with the physician and depression diagnosis was marginal,
though statistically signiﬁcant. CONCLUSIONS: When seeing
their primary care physician for reasons unrelated to mental
health or social problems, patients who were age 25–64, female,
self-pay or visiting for a chronic illness were substantially more
likely to be diagnosed with depression.
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TRENDS IN PHARMACOLOGIC TREATMENT FOR PATIENTS
WITH BIPOLAR: 1992–2002
Cooper LM, Zhao Z, Zhu B
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVE: Assess trends in pharmacologic treatment for
patients with bipolar disorder. METHODS: A large claims data-
base of insured individuals from October 1992 to September
2002 was analyzed to identify patients diagnosed with bipolar
disorder (ICD9-CM: 296.4x–296.8x). Treatment regimens were
examined for six-classes of psychotropics (antidepressants,
mood-stabilizers, atypical and typical antipsychotics, anxiolytics
and hypnotics). RESULTS: Of 13,407 patients, the percent
untreated remained stable around 10% over the 10-year period.
Among treated patients, about 65% received mood stabilizers
and/or antidepressants. The two agents most frequently used
were valproate (39.7%) and olanzapine (24.2%) in 2002.
Overall, mood stabilizers increased slightly from 59.5% to
64.2%, and atypical antipsychotics increased from 4.5% to
45.1% usage. Antidepressants and anxiolytics remained stable
at around 65% and 50% respectively, although the products
chosen shifted with new market introductions. Typical antipsy-
chotics decreased from 34.5% to12.4%, and hypnotics
decreased from 13.2% to around 7% usage. CONCLUSIONS:
Although about two-thirds of patients with bipolar illness receive
mood stabilizers, there continues to be opportunity for improve-
ment in pharmacotherapy. It is also important to understand out-
comes associated with changing treatment patterns for bipolar
patients.
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PATTERNS OF PHARMACOLOGIC TREATMENT FOR
PATIENTS WITH BIPOLAR DISORDER
Zhu B, Zhao Z, Cooper LM
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVE: Assess recent pharmacologic treatment patterns
for patients with bipolar disorder. METHODS: A large claims
database of insured individuals from October 1998 to Septem-
ber 2002 was analyzed to identify patients diagnosed with
bipolar disorder (ICD9-CM: 296.4x–296.8x). Treatment regi-
mens were examined for six-classes of psychotropics (antide-
pressants, mood-stabilizers, atypical and typical antipsychotics,
anxiolytics and hypnotics) during the year post-diagnosis. Dif-
ferences in medication use among sub-types of bipolar were
compared. RESULTS: Of 6373 patients (56.4% female, mean
age 49.2 years), 19.4% were depressed, 14.2% manic, 21.2%
mixed, and 45.1% other episodes; 9.1% didn’t receive psy-
chotropic treatment. Among treated patients, 66.0% received
antidepressants, 64.0% mood-stabilizers, 48.2% anxiolytics,
and 42.1% atypical antipsychotics. Valproate (40.3%) and olan-
zapine (22.0%) were top two most commonly prescribed psy-
chotropics. Only 22.7% received single-class therapy, 44.2%
received ≥3 classes and 19.8% received ≥5 classes of psy-
chotropics. Among depressed patients, 76.7% received antide-
pressants, 59.2% received mood-stabilizers and 39.9% received
atypical antipsychotics versus 45.4%, 71.2% and 54.4% in
manic patients, respectively. Surprisingly, 52.3% of depressed
patients received anxiolytics—the highest percentage among all
sub-types of bipolar patients. CONCLUSIONS: Pharmacother-
apy for bipolar patients is complex. Nearly half of bipolar
patients were treated with3 classes of psychotropics. Depressed
patients were more likely to receive antidepressants and anxi-
olytics but less likely to receive mood-stabilizers.
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PHARMACOLOGIC TREATMENT PATTERNS FOR 
BIPOLAR DISORDER
deLay N1, Stensland MD1,Viswanathan S2, Ciaglia M3
1Eli Lilly and Company, Indianapolis, IN, USA; 2ZS Associates, Boston,
MA, USA; 3ZS Associates, Evanston, IL, USA
OBJECTIVE: To examine managed-care treatment patterns for
patients diagnosed with bipolar disorder. METHODS: We exam-
ined the PharMetrics Integrated Outcomes Database of adjudi-
cated medical and pharmaceutical claims for over 3 million
patients from 11 U.S. health plans. We identiﬁed 4,455 bipolar
patients based on the following criteria: two claims with ICD-9-
CM diagnosis for bipolar disorder (296.0, 296.1, 296.4–296.8),
age between 10 and 64, and 1 year of continuous eligibility prior
to and following the initial bipolar diagnosis with claims begin-
ning January 1, 1999. RESULTS: Of the 4455 bipolar patients,
80% (3555) received medication-based treatment in a 13-month
window around the index diagnosis (12 months post and 1
month pre). A total of 38% of bipolar patients used 4 or more
medications during the 13 months. On average each patient
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underwent 3.6 distinct medication regimens with each, on
average, having 2 drugs. Poly-pharmacy (multiple drug combi-
nation) treatments represent 60% of the days of treatment and
a disproportionate 82% share of costs. Average paid cost per day
of treatment for those using poly-pharmacy is $7.56, whereas
monotherapy is $2.47. Twenty-three percent of patients are
treated with poly-pharmacy initially and permanently. Anti-
psychotics and benzodiazapine-based treatments are most com-
monly seen (80%) in poly-pharmacy treatments. Increasing
severity of illness is related to increased poly-pharmacy, with the
exception of those patients in remission. CONCLUSION: Phar-
macologic treatment of bipolar is challenging, individualized and
characterized by poly-pharmacy, reﬂecting the cyclical nature of
the disorder. The impact of the complexity of treating bipolar
needs to be studied to determine how service utilization and costs
are inﬂuenced.
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WHEN BIPOLAR DISORDER IS BEING IDENTIFIED: PHASE OF
DISORDER, PROVIDER SPECIALTY, FACILITY TYPE,AND
RESOURCE UTILIZATION SURROUNDING THE INITIAL
BIPOLAR DIAGNOSIS IN CLINICAL PRACTICE
Stensland MD1, deLay N1,Viswanathan S2, Ciaglia M3
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OBJECTIVE: In part because of its cyclical nature, bipolar dis-
order is frequently missed or misdiagnosed in clinical practice.
Over one third of bipolar patients report a period of 10+ years
between initially seeking treatment and proper diagnosis. Under-
standing when and where bipolar disorder is being diagnosed
represents an important step for targeting efforts to improve the
accurate identiﬁcation of bipolar patients. METHODS: To
examine characteristics of initial bipolar diagnosis, the Phar-
Metrics Integrated Outcomes Database of adjudicated medical
and pharmaceutical claims for over 3 million patients from 11
U.S. health plans was utilized. We identiﬁed 3,648 bipolar
patients based on the following criteria: two claims with ICD-9-
CM diagnosis for bipolar disorder (296.0, 296.1, 296.4–296.8)
that were not accompanied by a unipolar depression or schizo-
phrenia claim on the same day, age between 10 and 64, and 1
year of continuous eligibility prior to and following the initial
bipolar diagnosis. RESULTS: Of the 3648 patients, 1859 (51%)
had sufﬁcient diagnostic information to identify the current
phase of the disorder. Of these 1859 patients, 69% were diag-
nosed during either a manic or mixed episode. Most frequently
the diagnostic claim was associated with a mental health spe-
cialist (64%), with only 7% being associated with a family or
general practitioner. The majority of index diagnoses were at
outpatient visits (75%), followed by inpatient hospitals (15%),
and Emergency Rooms (2%). On average, patients incurred
$9241 in paid claims per year, of which $2610 (28%) occurred
in the 2 weeks before and after the bipolar index date. During
this month surrounding initial diagnosis, hospitalizations
accounted for 72% of the costs. CONCLUSIONS: Bipolar dis-
order appears to be most commonly diagnosed at outpatient
visits by mental health specialists when symptoms of mania are
present. Earlier recognition and treatment may reduce the spike
in costs that surrounds the initial diagnosis.
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MEDICATION PRESCRIBING PATTERNS FOR PATIENTS WITH
BIPOLAR DEPRESSION
deLay N1,Viswanathan S2, Ciaglia M3, Stensland MD1, Zhao Z1,
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OBJECTIVE: To examine managed-care prescribing patterns for
patients beginning pharmacologic treatment in the depressive
phase of bipolar. METHODS: This retrospective study
(1995–2002) included a cohort of 1203 patients who had 3 con-
secutive years of data, received an ICD coded diagnosis of
bipolar depression and received one of four classes of psy-
chotropic medication (i.e. antidepressant, antipsychotic, benzo-
diazapine, or mood stabilizer). Treatment patterns were observed
for a one-year period post diagnosis. RESULTS: Seventy-seven
percent of extracted data was between 1999–2002. Fifty-ﬁve dif-
ferent medications were used to create multiple unique mono
and/or combination pharmacologic treatments. Nine percent of
patients began their treatment in accordance with APA guide-
lines, whereas, 16% began treatment using only an antidepres-
sant. As switches in treatment occur, use of mono-therapy
treatments decrease (-12%) and use of four or more medication
combinations increase (+9%). One third of patients were treated
with four or more medications in combination, at some point,
during the year following diagnosis. CONCLUSION: Pharma-
cologic treatment of bipolar depression is characterized by poly-
pharmacy, reﬂecting the complexity of the disorder; and is often
not aligned with guidelines. There is a need to study how these
patterns impact service utilization and costs, as well as to further
understand the treatment patterns.
MENTAL HEALTH
MENTAL HEALTH—Methods
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DEPRESSION IN THE GENERAL POPULATION AND AFTER
STROKE: A PSYCHOMETRIC COMPARISON USING THE CES-D
SCALE
Pickard AS1, Dalal M1, Bushnell DM2
1University of Illinois at Chicago, Chicago, IL, USA; 2Health Research
Associates, Inc, Mountlake Terrace, WA, USA
OBJECTIVES: To assess the construct validity and reliability of
the Center for Epidemiologic Studies Depression (CES-D) scale
in stroke patients, and to examine item functioning in depressed
stroke patients compared to generalized depression.
METHODS: Psychometric analyses were conducted on sec-
ondary data sources, including 101 patients 3, months post-
stroke (of whom 32 were depressed), and 366 individuals with
depression from the US general population. Presence of (poten-
tial) depression was based on a CES-D score ≥16. Convergent
validity of the CES-D scale in stroke patients was assessed with
concurrently administered measures—the SF-36 mental health
subscale (MH), and the Health Utilities Index Mark 2 and 3
single attribute utility score for emotion (HUI2-E, HUI3-E,
respectively)—using Spearman’s rank correlation coefﬁcients (r).
Internal consistency reliability was assessed using Cronbach’s a.
Rasch analysis was used to compare item hierarchies and to iden-
tify differential item functioning (DIF) between generalized
depression and depression after stroke. RESULTS: The CES-D
was strongly correlated with the MH subscale (r = -0.81), HUI2-
E (r = -0.71) and HUI3-E (r = -0.66). Internal consistency reli-
ability of the CES-D scale in stroke patients was satisfactory
(Cronbach’s a = 0.90). Rasch analysis identiﬁed several items that
were redundant or did not contribute to scale consistency. Item
hierarchies separated into similar strata of difﬁculty for
depressed stroke patients and generalized depression, with inter-
personal disruption items (people unfriendly, feeling disliked)
being the most difﬁcult to endorse in both samples. DIF between
generalized depression and stroke was identiﬁed on items relat-
ing to appetite, restless sleep, crying, and feeling disliked. CON-
